@article {8137,
	title = {Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial},
	journal = {Journal of Clinical Oncology},
	volume = {17},
	year = {1999},
	note = {Cited By :123Export Date: 21 February 2017},
	month = {1999},
	pages = {914 - 920},
	abstract = {Purpose: To evaluate the tolerance and efficacy of the combination of docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Fifty-one chemotherapy-naive patients with NSCLC were treated with gemcitabine 900 mg/m2 intravenously on days 1 and 8 and docetaxel 100 mg/m2 intravenously on day 8 with granulocyte colony-stimulating factor (150 μg/m2, subcutaneously) support from day 9 to day 15. Treatment was repeated every 3 weeks. Results: The patients{\textquoteright} median age was 64 years. The World Health Organization performance status was 0 to 1 in 39 patients and 2 in 12 patients. Fifteen patients (29\%) had stage IIIB disease, and 36 (71\%) had stage IV; histology was mainly squamous cell carcinoma (59\%). A partial response was achieved in 19 patients (37.5\%; 95\% confidence interval, 24\% to 50\%); stable disease and progressive disease were each observed in 16 patients (31.4\%). The median duration of response and the time to tumor progression were 5 and 6 months, respectively. The median survival was 13 months, and the actuarial 1-year survival was 50.7\%. Grade 4 anemia and thrombocytopenia were rare (2\%). Four patients (8\%) developed grade 3 or 4 neutropenia, and all were complicated with fever; there was no treatment-related death. Grade 3 or 4 diarrhea occurred in three patients (6\%), grade 2 or 3 neurotoxicity in four patients (8\%), grade 2 or 3 asthenia in 10 patients (20\%), and grade 2 or 3 edema in 10 patients (20\%). Conclusion: The combination of docetaxel/gemcitabine is well tolerated, can be used for outpatients, and is active for the treatment of advanced NSCLC. This treatment merits further comparison with other cisplatin- or carboplatin-based combinations.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033014303\&partnerID=40\&md5=fd098621632fb84876718c41aeefbae0},
	author = {Georgoulias, V. and Kouroussis, C. and Androulakis, N. and Kakolyris, S. and Dimopoulos, M.-A. and Papadakis, E. and Bouros, D. and Apostolopoulou, F. and Papadimitriou, C. and Agelidou, A. and Hatzakis, K. and Kalbakis, K. and Kotsakis, A. and Vardakis, N. and Vlachonicolis, J.}
}
